Secondary Logo

Journal Logo

Prognostic and clinicopathological significance of long non-coding RNA UCA1 in colorectal cancer

Results from a meta-analysis

Liu, Xiaoqun MDa; Liu, Xiangdong MDb; Qiao, Tiankui MDa,∗; Chen, Wei MDa

Section Editor(s): Ding., Jianxun

doi: 10.1097/MD.0000000000018031
Research Article: Systematic Review and Meta-Analysis
Open

Objective: Urothelial cancer-associated 1 (UCA1), an oncogenic long non-coding RNA, was aberrantly upregulated in colorectal cancer (CRC). This study aimed to further explore the clinical value of UCA1 in CRC.

Methods: Eligible studies were retrieved by searching Pubmed, Embase, Cochrane Library, Web of Science, Chinese National Knowledge Infrastructure, and Wanfang databases. Pooled hazard ratio (HR) and odds ratio (OR) with 95% confidence interval (CI) were applied to assess the prognostic role and clinical significance of UCA1.

Results: A total of 7 eligible studies with 775 cancer patients were recruited in the meta-analysis. The results showed that UCA1 overexpression was significantly correlated with poor overall survival in patients with CRC (HR = 2.25, 95% CI: 1.77–2.87, P < .001). There was also a significantly negative association between high UCA1 levels and tumor differentiation (OR = 2.84, 95% CI: 1.87–4.31, P < .001), lymph node metastasis (OR = 3.48, 95% CI: 2.24–5.41, P < .001), distant metastasis (OR = 2.67, 95% CI: 1.32–5.38, P = .006), tumor node metastasis stage (OR = 3.01, 95% CI: 2.16–4.18, P < .001), tumor invasion depth (OR = 2.18, 95% CI: 1.03–4.61, P = .04), and tumor size (OR = 2.27, 95% CI: 1.56–3.32, P < .001).

Conclusions: Our study revealed that UCA1 overexpression was associated with poor prognosis and more advanced clinicopathological features, suggesting that UCA1 may serve as an indicator for unfavorable outcome of patients with CRC.

aCenter for Tumor Diagnosis and Therapy

bDepartment of Ophthalmology, Jinshan Hospital, Fudan University, Shanghai, China.

∗Correspondence: Tiankui Qiao, Center for Tumor Diagnosis and Therapy, Jinshan Hospital, Fudan University, Longhang Road 1508, Jinshan District, Shanghai, China (e-mail: 18019206896@163.com).

Abbreviations: ceRNA = competing endogenous RNA, CI = confidence interval, CNKI = Chinese National Knowledge Infrastructure, CRC = colorectal cancer, CREB1 = cyclic adenosine 3′,5′-monophosphate response element binding protein 1, HR = hazard ratio, lncRNA = long non-coding RNA, NOS = Newcastle-Ottawa Scale, OR = odds ratio, OS = overall survival, qRT-PCR = quantitative reverse transcription-polymerase chain reaction, UCA1 = urothelial cancer-associated 1, ZEB1 = zinc finger E-box binding homeobox 1.

How to cite this article: Liu X, Liu X, Qiao T, Chen W. Prognostic and clinicopathological significance of long non-coding RNA UCA1 in colorectal cancer: Results from a meta-analysis. Medicine. 2019;98:48(e18031).

X-QL and X-DL contributed equally to this work.

The authors have no conflicts of interest to disclose.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0

Back to Top | Article Outline

1 Introduction

Colorectal cancer (CRC) is not only the fourth most frequent malignancy but also ranks as the fourth leading cause of cancer-related death worldwide, which has threatened human health seriously. According to the GLOBOCAN 2018 database, approximately 1.8 million new cases and 861,600 deaths were caused by CRC in 2018.[1] Although great advances on therapy strategies have been achieved, the clinical outcome of CRC still is far away from satisfaction.[2] Therefore, there is an urgent need to understand the precise molecular mechanisms underlying tumorigenesis as well as to identify new therapeutic targets for CRC. Nowadays, advantage of molecular biomarkers in diagnosis and prognosis of multiple malignancies has been highlighted, which might provide more exact clues for supervising individual therapy and monitoring disease progression.[3,4]

Long non-coding RNAs (lncRNAs), accounting for 70% of the human genome, are defined as a class of RNA molecules with length larger than 200 nucleotides.[5] In the past, lncRNAs were once considered as transcriptional noise in the genomic RNAs. However, a growing body of evidence has suggested the regulation role of lncRNAs on gene expression at the epigenetic, transcriptional, or posttranscriptional levels.[6,7] In particular, the effect of lncRNAs on tumorigenesis has attracted attention recently and become widely acceptable.[8] More importantly, the expression of lncRNAs was indicated to be dysregulated in multiple malignancies, which is responsible for diverse biological processes, such as tumor cell proliferation, apoptosis, invasion, and metastasis.[9,10] Subsequently, emerging evidence has suggested that there was a significant association between aberrant expression of lncRNAs and progression of disease, including clinicopathological features and survival, which indicates that lncRNAs may serve as molecular biomarkers for various malignancies.[11]

Urothelial cancer-associated 1 (UCA1), a novel lncRNA and locating in the chromosome 19p13.12, was originally discovered to be up-regulated in bladder transitional cell carcinoma in 2006 and could promote cell proliferation and transformation.[12,13] Recently, overexpressed UCA1 has attracted great concerns due to its involvement in diverse malignancies, especially CRC.[14,15] However, these results were limited by small sample scales or inconsistent conclusions. For instance, Han et al[14] demonstrated that UCA1 expression was related with differentiated histology and invasion depth of CRC, whereas Jiang et al[15] illustrated that UCA1 was correlated with differentiation rather than invasion depth. Until now, meta-analysis associated UCA1 has not yet to be performed in CRC. Therefore, with the aim to investigate the potentially clinical value of UCA1, relevant articles were collected to perform this comprehensive meta-analysis for assessing the correlation of UCA1 expression with clinicopathological features and prognosis in patients with CRC.

Back to Top | Article Outline

2 Material and methods

2.1 Literature search strategy

To get access to potentially eligible studies, relevant literatures exploring the association of UCA1 with clinicopathological features and prognosis of CRC were systematically retrieved in Pubmed, Web of Science, Cochrane Library, Embase, Chinese National Knowledge Infrastructure (CNKI), and Wanfang databases updated to January 2019. To increase the sensitivity of the search, both MeSH terms and free-text words were used in the retrieval strategy. Relevant retrieval terms are as follows: “UCA1” or “urothelial cancer-associated 1”, “cancer” or “carcinoma” or “tumor” or “neoplasm”, and “survival” or “prognosis” or “prognostic” or “progression” or “metastasis” or “clinicopathological”. In addition, the reference lists in relevant articles were screened manually in case of the omission of any potentially relevant literature. Because the data were obtained from publicly available databases, additional approval by an ethics committee was not applicable.

Back to Top | Article Outline

2.2 Inclusion and exclusion criteria

Inclusion and exclusion criteria were formulated to screen the publications. The eligible studies met the following inclusion criteria:

  • (1) the association of UCA1 with progression of CRC was explored,
  • (2) the expression of UCA1 in primary cancerous tissues were detected,
  • (3) patients were grouped according to the expression levels of UCA1, and
  • (4) relevant clinicopathological parameters were described.

Exclusion criteria included

  • (1) duplicate publications,
  • (2) no original articles, reviews, letters, case reports, and commentaries,
  • (3) studies focusing on UCA1 in other types of cancers rather than CRC,
  • (4) studies using non-tissue samples, and
  • (5) studies lack of usable data.

For multiple publications from the same medical center, only the most recent or the most complete study was included in the meta-analysis.

Back to Top | Article Outline

2.3 Data extraction

According to the inclusion and exclusion criteria, two investigators (X-QL and X-DL) deliberatively reviewed and collected the essential information from the eligible studies independently, For any discrepancy, a consensus was achieved through discussion with a third investigator (T-KQ). For each eligible study, the following information was collected: the first author’ name, publication year, country, cancer type, sample size, detection method of UCA1 expression, cut-off value, number of patients in high/low UCA1 expression group, follow-up period, outcome measures, survival analysis methods (univariate or multivariate), and hazard ratio (HR) and corresponding 95% confidence interval (CI) for overall survival (OS). If the HRs with their 95% CIs were provided in the original studies, these available data were extracted directly. When an included study gave only Kaplan–Meier survival curves, the survival data was digitized by the Engauge Digitizer version 4.1 software (http://digitizer.sourceforge.net/) and calculated as described by Tierney et al.[16]

Back to Top | Article Outline

2.4 Quality assessment

The quality of all included studies was assessed according to the Newcastle-Ottawa Scale (NOS) criteria for cohort studies.[17] The NOS criteria is scored based on three aspects, including subject selection, comparability of subject, and clinical outcome, with the final scores ranging from 0 (lowest) to 9 (highest). A study with the NOS scores more than 6 was regarded as high quality.

Back to Top | Article Outline

2.5 Statistical analysis

Statistical analysis was performed with Review Manager 5.2 (The Cochrane Collaboration, Oxford, UK) and stata SE12.0 (Stata Corporation, TX). HRs and corresponding 95% CIs were used to assess the association between UCA1 and OS in CRC, with HR > 1 indicating that the patients with high UCA1 expression had a poor prognosis. Odds ratios (ORs) and their 95% CIs were used to evaluate the association between UCA1 and clinicopathological features in patients of CRC. The between-studies heterogeneity was assessed with the Chi square-based Q test and I2 statistics. A P value < .05 or I2 > 50% indicated significant heterogeneity, in which case a random-effect model was applied, otherwise, a fixed-effect model was used. Subgroup analysis was performed to further investigate the prognostic value of UCA1 in CRC. Sensitivity analyses were employed to access the stability of the results. The potential publication bias was evaluated with funnel-plot analysis as well as Egger's test. All the P values were determined by two-sided tests, and P < 0.05 was considered statistically significant.

Back to Top | Article Outline

3 Results

3.1 Literature information

As shown in the flow diagram (Fig. 1), a total of 235 records were retrieved by searching Pubmed, Web of Science, Cochrane Library, Embase, CNKI, and Wanfang databases. Initially, 5 records were removed because of duplication. After the title and abstract were screened, 132 articles were excluded due to either no original articles or reviews or case reports or commentaries. Subsequently, full text was assessed carefully and 91 articles were found to be ineligible due to lack of available outcome or inappropriate study design or for focusing on the level of UCA1 from other type of cancers rather than CRC. Finally, 7 studies[14,15,18–22] comprising 775 patients were identified as eligible for the present quantitative analysis, including 6 on OS and 7 on clinicopathological features.

Figure 1

Figure 1

Back to Top | Article Outline

3.2 Study characteristics

The main characteristics and data of the inclusion studies were summarized in Table 1. As shown, all studies were conducted in China and published between 2014 and 2018 with sample scales ranging from 54 to 185. Tumor node metastasis (TNM) staging ranged from stage I to IV. The longest follow-up period was up to 120 months. The UCA1 expression was detected with quantitative reverse transcription-polymerase chain reaction (qRT-PCR) in all studies. The cut-off value of UCA1 levels was based on median value in 4 studies, mean value in 2 studies, and fourth quartile value in 1 study. With inconsistent cut-off value due to different criteria, all participants in the inclusion studies were categorized into high and low UCA1 expression groups. HRs with corresponding 95% CIs were extracted from multivariate analysis in 5 studies and univariate analysis in 5 studies (estimated effects collected from Kaplan–Meier survival curve in 2 studies). All of the included studies got 7 scores or more according to the NOS criteria, which indicated their high quality of methodology.

Table 1

Table 1

Back to Top | Article Outline

3.3 Association between UCA1 and OS

A total of 6 studies of 715 patients reported the association between UCA1 expression levels in cancer tissues and OS of CRC. As shown in Figure 2, the fixed-effect model was applied to calculate the pooled HR and its 95% CI since no significant heterogeneity was found among these studies (I2 = 0%, P = .44). The results revealed that high UCA1 expression was significantly associated with poor OS (HR = 2.25, 95% CI: 1.77–2.87, P < .001). Although there was no significant between-studies heterogeneity, the subgroup meta-analysis was conducted based on analysis type, sample size, and cut-off value for a subsequent investigation of potential heterogeneity. From the subgroup results by analysis type (Fig. 3A), we found that UCA1 similarly was a significantly prognostic indicator of OS in multivariable analysis subgroup (HR = 2.39, 95% CI: 1.80–3.16, P < .001) and univariable analysis subgroup (HR = 2.65, 95% CI: 1.93–3.63, P < .001), without statistically significant heterogeneity in the two subgroups (I2 = 8.0%, P = .36 and I2 = 25%, P = .25, respectively). Then, elevated UCA1 was also found to be significantly associated with OS of patients in studies with sample sizes both equal or greater than 90 (HR = 2.17, 95% CI: 1.62–2.91, P < .001) and less than 90 (HR = 2.44, 95% CI: 1.59–3.74, P < .001), with significant heterogeneity in the former (I2 = 59%, P = .09) but not in the latter (I2 = 0%, P = .87) (Fig. 3B). Meanwhile, a significant relationship between UCA1 expression and OS of patients was observed in studies with median as cut-off value (HR = 2.25, 95% CI: 1.73–2.93, P < .001) and non-median as cut-off value (HR = 2.25, 95% CI: 1.26–4.02, P = .006), without evidence of significant heterogeneity across the two subgroups (I2 = 27%, P = .24 and I2 = 0%, P = .53, respectively) (Fig. 3C). Results from the above analysis indicated that high UCA1 expression was significantly correlated with poor OS in CRC patients, suggesting that UCA1 was an indicator of decreased survival rate in CRC.

Figure 2

Figure 2

Figure 3

Figure 3

Back to Top | Article Outline

3.4 Association between UCA1 and clinicopathological features

In order to determine whether the expression of UCA1 was related to clinically pathological characteristics, the clinicopathological data were further collected for the meta-analysis. As shown in Table 2, a total of 7 studies including 670 cases reported the association of UCA1 overexpression with clinicopathological features of CRC. Except for tumor invasion depth (I2 = 72%, P = .007), there was no significant heterogeneity among studies for age (I2 = 49%, P = .12), gender (I2 = 2%, P = .41), location (I2 = 0.0%, P = .80), tumor size (I2 = 47%, P = .11), lymph node metastasis (I2 = 0.0%, P = 1.0), distant metastasis (I2 = 25%, P = .26), TNM stage (I2 = 36%, P = .16), histopathological grade (I2 = 26%, P = .23), lymphatic invasion (I2 = 0.0%, P = .73), and venous invasion (I2 = 0.0%, P = .78). The pooled results revealed that high UCA1 transcription levels were significantly associated with tumor differentiation (OR = 2.84, 95% CI: 1.87–4.31, P < .001), lymph node metastasis (OR = 3.48, 95% CI: 2.24–5.41, P < .001), distant metastasis (OR = 2.67, 95% CI: 1.32–5.38, P = .006), TNM stage (OR = 3.01, 95% CI: 2.16–4.18, P < .001), tumor invasion depth (OR = 2.18, 95% CI: 1.03–4.61, P = 0.04), and tumor size (OR = 2.27, 95% CI: 1.56–3.32, P < .001). However, no significant correlation was found with gender (OR = 0.81, 95% CI: 0.58–1.13, P = .21), age (OR = 0.91, 95% CI: 0.61–1.37, P = .66), lymphatic invasion (OR = 1.56, 95% CI: 0.88–2.75, P = .13), venous invasion (OR = 0.85, 95% CI: 0.39–1.85, P = .69), and nervous invasion (OR = 0.59, 95% CI: 0.18–1.95, P = .39). Taken together, the above results revealed that UCA1 overexpression was significantly correlated with poorer differentiation, deeper tumor invasion (T3 stage or more), higher risk of metastasis, and more advanced TNM stage in CRC patients, suggesting that UCA1 may serve as a risk factor for these unfavorably clinicopathologocal features of CRC.

Table 2

Table 2

Back to Top | Article Outline

3.5 Sensitivity analysis

In order to assess the stability of the pooled results, sensitivity analysis was performed using stata SE12.0 software to assess the effect of any single study on OS and clinicopathologic characteristics by omitting individual study at a time in total population. As shown in Figure 4, when each study was removed sequentially, none of the residual results were dramatically altered each time. Because of the limited number of studies and without between-studies heterogeneity, the sensitivity analysis was not performed in these groups of clinicopathologic covariates including age, location, lymph node metastasis, distant metastasis, lymphatic invasion, venous invasion, and nervous invasion.

Figure 4

Figure 4

Back to Top | Article Outline

3.6 Publication bias

The funnel plots were employed to assess the potential publication bias of the present meta-analysis. As shown, no publication bias was found in the studies with OS (Fig. 5A) or gender (Fig. 5B) or depth of tumor (Fig. 5C) or tumor differentiation (Fig. 5D) or TNM stage (Fig. 5E) or tumor size (Fig. 5F), which was confirmed in Egger's linear regression test using stata SE12.0 software (Table 3). Because of the small number of studies and little heterogeneity, the publication bias was not analyzed in the remaining clinicopathologic co-variate groups.

Figure 5

Figure 5

Table 3

Table 3

Back to Top | Article Outline

4 Discussion

Nowadays, CRC constitutes a major part of human cancers and still remains an important health challenge worldwide, especially in China.[1] Typically, due to lacking specific symptoms in the early stage of CRC, most patients are diagnosed in an advanced stage, which is responsible for an undesirable five-year survival rate.[23] Thus, it is urgent to identify more precise and specific biomarkers for improving diagnosis and evaluating prognosis.

Accumulating evidence demonstrated that the initiation and progression of malignant tumors was a multi-step process involving in aberrant expression of lncRNAs of multiple oncogenes and anti-oncogenes.[24,6] As one of oncogenic lncRNAs, UCA1 was showed extensive regulatory functions in diverse biological processes including cell proliferation, apoptosis, invasion, and cell cycle progression in various types of cancer.[25,26] In addition, UCA1 can also act as a competing endogenous RNA (ceRNA) by sponging to miR-204-5p and regulate the expression of miR-204-5p target genes, such as CREB1 and ZEB1, which is associated with migration and invasion.[27] Recently, a growing number of studies have uncovered that UCA1 expression was markedly upregulated in CRC tissues compared to adjacent normal tissues.[25,28] Furthermore, upregulated UCA1 has been found to play important roles in CRC occurrence and progression via exerting oncogenic function.[29,30] Meanwhile, it was also reported that a high level of UCA1 expression was closely correlated with a larger tumor size, poorer differentiated histology, and greater tumor depth.[14,18,21] More importantly, patients with high UCA1 expression had a poorer prognosis compared to patients with low UCA1 expression.[14,15,18,20–22]

The above-mentioned results suggested that UCA1 played a crucial regulatory role in the biological process of carcinogenesis and might serve as a potential target for treatment of CRC. However, the sample sizes in most studies were relatively small. Even, it was distinctive about the association between UCA1 overexpression and progression of CRC, such as invasion and metastasis. With the intent to identify the clinical value of UCA1 expression, a comprehensive meta-analysis was performed to investigate the relationship between UCA1 expression and clinicopathologic characteristics and assess prognosis role of UCA1 for CRC patients.

To our knowledge, this is the first meta-analysis to explore the clinical significance and prognostic value of UCA1 overexpression in CRC. Here, this meta-analysis on 7 eligible studies with a total of 775 patients was evaluated to provide evidences that UCA1 overexpression could predict advanced clinicopathological features and serve as an unfavorably risk factor for survival of patients with CRC. In these findings, the elevated UCA1 expression was negatively correlated with poor OS in patients with CRC. Meanwhile, subgroup analysis was performed and the pooled results would not be altered by other factors, such as sample size, analysis type, and cut-off value. In addition, the association between UCA1 expression and clinicopathological features was evaluated in patients with CRC. Totally, the results verified that high UCA1 expression was associated with worse histopathological grade, deeper tumor invasion, and more advanced TNM stage. Furthermore, the patients with UCA1 overexpression may have a higher risk of developing lymph node metastasis and distant metastasis. Besides, the sensitivity analysis also indicated the stability of this results.

Otherwise, it should be emphasized that several limitations existed in the current meta-analysis. First, all available studies were performed in Chinese population rather than worldwide population, suggesting that the clinical role of UCA1 should be taken cautiously in other regions and ethnicities. Second, the data of HR and 95% CIs estimated from Kaplan–Meier survival curves might be less accurate than that obtained directly from published statistical data, which might increase the potential bias. Third, the limited databases were used for retrieval and the included studies were of relatively small numbers as well as an inconsistent cut-off value of UCA1 expression, which might result in some heterogeneity. In addition, the power of the study was not defined and the statistical analysis measuring that the sample size is adequate enough to make any conclusions was not performed in our present study. Based on these limitations, the predictive significance of assessed UCA1 in these unfavorably clinicopathological covariates and poor prognosis of CRC patients might be overestimated to some extent.

Taken together, the present study revealed that UCA1 overexpression not only might predict a poor prognosis in CRC but also was associated with advanced tumor stage and high risks of metastasis, especially in Chinese population. In another word, UCA1 may serve as a promising biomarker to predict prognosis and progression of CRC. Considering the limitations existing in the present study, more large-scale and better designed studies should be required to conduct for further updating the findings of this analysis.

Back to Top | Article Outline

Acknowledgments

We sincerely thank the editors and anonymous reviewers for their hard work and thoughtful advices that have substantially helped improve this paper.

Back to Top | Article Outline

Author contributions

Conceptualization: Xiaoqun Liu, Xiangdong Liu.

Data curation: Xiaoqun Liu, Xiangdong Liu, Wei Chen.

Formal analysis: Xiaoqun Liu, Xiangdong Liu, Wei Chen.

Investigation: Xiaoqun Liu, Xiangdong Liu, Wei Chen.

Methodology: Xiaoqun Liu, Xiangdong Liu, Wei Chen.

Project administration: Xiaoqun Liu, Xiangdong Liu.

Resources: Xiaoqun Liu, Xiangdong Liu.

Software: Xiaoqun Liu, Xiangdong Liu.

Supervision: Xiaoqun Liu, Xiangdong Liu, Tiankui Qiao.

Validation: Xiaoqun Liu, Xiangdong Liu, Tiankui Qiao, Wei Chen.

Visualization: Xiaoqun Liu, Xiangdong Liu, Tiankui Qiao, Wei Chen.

Writing – original draft: Xiaoqun Liu, Xiangdong Liu.

Writing – review & editing: Xiaoqun Liu.

Back to Top | Article Outline

References

[1]. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.
[2]. Kong JC, Guerra GR, Pham T, et al. Prognostic impact of tumor-infiltrating lymphocytes in primary and metastatic colorectal cancer: a systematic review and meta-analysis. Dis Colon Rectum 2019;62:498–508.
[3]. Huang Z, Chen W, Du Y, et al. Serum miR-16 as a potential biomarker for human cancer diagnosis: results from a large-scale population. J Cancer Res Clin Oncol 2019;145:787–96.
[4]. Ilie M, Beaulande M, Hamila M, et al. Automated chromogenic multiplexed immunohistochemistry assay for diagnosis and predictive biomarker testing in non-small cell lung cancer. Lung Cancer 2018;124:90–4.
[5]. Naderi-Meshkin H, Lai X, Amirkhah R, et al. Exosomal lncRNAs and cancer: connecting the missing links. Bioinformatics 2019;35:352–60.
[6]. Rokavec M, Horst D, Hermeking H. Cellular model of colon cancer progression reveals signatures of mRNAs, miRNA, lncRNAs, and epigenetic modifications associated with metastasis. Cancer Res 2017;77:1854–67.
[7]. Mathy NW, Chen XM. Long non-coding RNAs (lncRNAs) and their transcriptional control of inflammatory responses. J Biol Chem 2017;292:12375–82.
[8]. Jiang S, Tan B, Zhang X. Identification of key lncRNAs in the carcinogenesis and progression of colon adenocarcinoma by co-expression network analysis. J Cell Biochem 2019;120:6490–501.
[9]. Huo X, Han S, Wu G, et al. Dysregulated long noncoding RNAs (lncRNAs) in hepatocellular carcinoma: implications for tumorigenesis, disease progression, and liver cancer stem cells. Mol Cancer 2017;16:165–75.
[10]. Chen Y, Yu X, Xu Y, et al. Identification of dysregulated lncRNAs profiling and metastasis-associated lncRNAs in colorectal cancer by genome-wide analysis. Cancer Med 2017;6:2321–30.
[11]. Zhou Q, Liu J, Quan J, et al. lncRNAs as potential molecular biomarkers for the clinicopathology and prognosis of glioma: a systematic review and meta-analysis. Gene 2018;668:77–86.
[12]. Wang XS, Zhang Z, Wang HC, et al. Rapid identification of UCA1 as a very sensitive and specific unique marker for human bladder carcinoma. Clin Cancer Res 2006;12:4851–8.
[13]. Wang F, Li X, Xie X, et al. UCA1, a non-protein-coding RNA up-regulated in bladder carcinoma and embryo, influencing cell growth and promoting invasion. FEBS Lett 2008;582:1919–27.
[14]. Han Y, Yang YN, Yuan HH, et al. UCA1, a long non-coding RNA up-regulated in colorectal cancer influences cell proliferation, apoptosis and cell cycle distribution. Pathology 2014;46:396–401.
[15]. Jiang H, Chen Y-T, Fu X-G. Tissue expression level of lncRNA UCA1 is a prognostic biomarker for colorectal cancer. Int J Clin Exp Pathol 2016;9:4241–6.
[16]. Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16–21.
[17]. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603–5.
[18]. Bian Z, Jin L, Zhang J, et al. LncRNA-UCA1 enhances cell proliferation and 5-fluorouracil resistance in colorectal cancer by inhibiting miR-204-5p. Sci Rep 2016;6:23892–7.
[19]. Cui M, Chen M, Shen Z, et al. LncRNA-UCA1 modulates progression of colon cancer through regulating the miR-28-5p/HOXB3 axis. J Cell Biochem 2019;1–1. [Epub ahead of print].
[20]. Ni B, Yu X, Guo X, et al. Increased urothelial cancer associated 1 is associated with tumor proliferation and metastasis and predicts poor prognosis in colorectal cancer. Int J Oncol 2015;47:1329–38.
[21]. Tao K, Yang J, Hu Y, et al. Clinical significance of urothelial carcinoma associated 1 in colon cancer. Int J Clin Exp Med 2015;8:21854–60.
[22]. Yao K, Zhu GH, Shan YZ. Expressions of long noncoding RNA TUG1 and UCA1 in colon cancer tissue and their clinical significance. Chin J Gen Surg 2018;27:449–56.
[23]. Rebersek M, Mesti T, Boc M, et al. Molecular biomarkers and histological parameters impact on survival and response to first-line systemic therapy of metastatic colorectal cancer patients. Radiol Oncol 2019;53:85–95.
[24]. Rathinasamy B, Velmurugan BK. Role of lncRNAs in the cancer development and progression and their regulation by various phytochemicals. Biomed Pharmacother 2018;102:242–8.
[25]. Barbagallo C, Brex D, Caponnetto A, et al. LncRNA UCA1, upregulated in CRC biopsies and downregulated in serum exosomes, controls mRNA expression by RNA-RNA interactions. Mol Ther Nucleic Acids 2018;12:229–41.
[26]. Jahangiri B, Khalaj-Kondori M, Asadollahi E, et al. Cancer-associated fibroblasts enhance cell proliferation and metastasis of colorectal cancer SW480 cells by provoking long noncoding RNA UCA1. J Cell Commun Signal 2019;13:53–64.
[27]. Liang C, Yang Y, Guan J, et al. LncRNA UCA1 sponges miR-204-5p to promote migration, invasion and epithelial-mesenchymal transition of glioma cells via upregulation of ZEB1. Pathol Res Pract 2018;214:1474–81.
[28]. Yang X, Liu W, Xu X, et al. Downregulation of long non coding RNA UCA1 enhances the radiosensitivity and inhibits migration via suppression of epithelial mesenchymal transition in colorectal cancer cells. Oncol Rep 2018;40:1554–64.
[29]. Neve B, Jonckheere N, Vincent A, et al. Epigenetic regulation by lncRNAs: an overview focused on UCA1 in colorectal cancer. Cancers (Basel) 2018;10:440–73.
[30]. Song F, Li L, Liang D, et al. Knockdown of long noncoding RNA urothelial carcinoma associated 1 inhibits colorectal cancer cell proliferation and promotes apoptosis via modulating autophagy. J Cell Physiol 2019;234:7420–34.
Keywords:

colorectal cancer; long non-coding RNA (lncRNA); meta-analysis; prognosis; urothelial cancer-associated 1

Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc.